- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03993743
A Study of CD147-targeted CAR-T by Hepatic Artery Infusions for Very Advanced Hepatocellular Carcinoma
August 24, 2019 updated by: Chen Zhinan, Xijing Hospital
An Open-label, Dose Escalation Clinical Study to Access the Safety and Clinical Activity of CD147-targeted CART by Hepatic Artery Infusions for Very Advanced Hepatocellular Carcinoma
This is a single-center, single-arm, open label and dose escalation clinical study of anti-CD147 CART cells by hepatic artery infusions in patients with advanced hepatocellular carcinoma.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Patients autologous T cells are activated and then engineered to express chimeric antigen receptors (CARs) specific for CD147(CD147-CART).
CAR-T cells are expanded in culture and returned to the patient by hepatic artery infusion at specific cell doses.
Four CD147-CART doses patient are planned at 1-week intervals.
Tumor biopsies will be obtained at the time of the initial diagnostic angiogram and during the first infusion session.
Serum cytokine level and CAR-T cell number will be measured in whole treatment session.
Study Type
Interventional
Enrollment (Anticipated)
34
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Zhi-Nan Chen, PhD
- Phone Number: 86-029-84774547
- Email: znchen@fmmu.edu.cn
Study Contact Backup
- Name: Kaishan Tao, Dr
- Phone Number: 86-029-84775259
- Email: taokaishan0686@163.com
Study Locations
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710032
- Recruiting
- Department of hepato-biliary & Pancreato Splenic Surgery Organ Transplant Center, Xijing Hospital
-
Contact:
- Kaishan Tao, Dr
- Email: taokaishan0686@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age ≥ 18 year and ≤ 65 years, both male and female.
- Advanced hepatocellular carcinoma(HCC) patient, which is untreatable by surgery or local therapy, or has postoperative progressions, failed at least one and two line of standard systemic chemotherapy, and unwilling or intolerance to targeting therapy or immune-therapy of cancer.
- The portal vein is not total occlusion, or collateral circulation has formed between hepatic artery and blocked portal vein.
- Patient with measurable HCC focus defined by mRECIST.
- Patient with histologically confirmed diagnosis of CD147+ hepatocellular carcinoma.
- Adequate venous access for apheresis, and no other contraindications for apheresis.
- Child-Pugh score ≤7.
- Eastern Cooperative Oncology Group(ECOG) performance status of 0-2.
- Patient with a life expectancy of greater than three months.
- Patients must able to understand and be willing to sign an informed consent.
Exclusion Criteria:
- Patients with fibrolamellar carcinoma of liver,mixed hepatocellular carcinoma or cholangiocarcinoma.
- Patients with severe hypohepatia including jaundice, hepatic encephalopathy, refractory ascites or hepatorenal syndrome.
Patients with severe comorbidity, including any of the following.
- Unstable angina pectoris and/or congestive heart failure need hospitalization;
- Myocardial infarction or cerebrovascular accident (CVA) in the last 6 months;
- chronic obstructive pulmonary disease progressions or need hospitalization;
- severe cardiovascular, nervous system, hematological, gastrointestinal, endocrine diseases or metabolic disorders;
- autoimmune disease or immunodeficiency disease;
- acute bacterial infections or fungal infections needs intravenous injection of antibiotics during CAR-T cell therapy;
- tuberculosis not cured;
- other malignancies;
- Patients who have received gene therapy, cell therapy or immune therapy.
- Patients who have received organ transplantation.
- Patients who have received treatment of targeted drugs, glucocorticoid or immunosuppressive drugs within 2 weeks before enrolling in clinical trial.
- Patients who have received chemotherapy except for lymphocyte clearance within 2 weeks before enrolling in clinical trial.
- Patients who have received radiotherapy.
- Patients who did not recover to CTCAE(v5.0) grade 1 from adverse events (except hair)of previous anti-tumor therapy before enrolling in trial.
- Syphilis test (TRUST) positive, Anti-HIV positive, Anti-HCV positive with HCV-RNA level higher than the lower limit of detection(LOD), or HBcAb positive with HBV-DNA level higher than the LOD.
Patients with following abnormalities:
- Absolute neutrophil count (ANC) < 1.5E9/L, platelet(PLT) < 50E9/L, or hemoglobin(HGB)< 80 g/dL;
- Prothrombin time (PT), activated partial thromboplastin time (APTT) or international normalized ratio (INR) > 1.5×ULN (upper normal value);
- Total bilirubin(TBIL) > 2×ULN; ALT, AST or ALP>5×ULN;
- Serum creatinine (Cr)≥1.5×ULN or glomerular filtration rate (GFR) < 60 mL/min·1.73m^2;
- left ventricular ejection fraction (LVEF) < 50%;
- Patients with a history of allergic reactions attributed to any agents or compounds involved in this study.
- Patients with a history of mental disorders.
- Patients with a history of drug abuse.
- Pregnant and lactating women.
- Patients of childbearing age who unwilling or unable to take birth control from during this study and 3 months post this study.
- Patients who receive any other investigational agents within the 3 months before enrolling in this clinical trial.
- Investigator considers not suitable for this trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: CD147-CART
Infusions of CD147-CART cells over the course of each week for 3 times into the hepatic artery
|
Three infusions of CD147-CART cells over the course of three weeks into the hepatic artery.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence and type of adverse events induced by CD147-CART hepatic artery infusions
Time Frame: 12 weeks
|
To assess the safety of CD147-CART (anti-CD147 CAR-T cell) hepatic artery infusions (HAI) for very advanced hepatocellular carcinoma which measured by number and type of adverse events.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
DLT and MTD of CD147-CART cell hepatic artery infusions
Time Frame: 12 weeks
|
To determine the dose limited toxicity (DLT) and maximum tolerated dose (MTD) of CD147-CART hepatic artery infusions.
|
12 weeks
|
Activity of CD147-CART cell hepatic artery infusions
Time Frame: 2 years
|
To evaluate treatment response of CD147-CART hepatic artery infusions for very advanced hepatocellular carcinoma.
|
2 years
|
CD147-CART detection in extrahepatic sites
Time Frame: 2 years
|
Quantification of CD147-CART cells in blood samples.
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
May 27, 2019
Primary Completion (ANTICIPATED)
October 27, 2020
Study Completion (ANTICIPATED)
May 27, 2022
Study Registration Dates
First Submitted
June 19, 2019
First Submitted That Met QC Criteria
June 19, 2019
First Posted (ACTUAL)
June 21, 2019
Study Record Updates
Last Update Posted (ACTUAL)
August 28, 2019
Last Update Submitted That Met QC Criteria
August 24, 2019
Last Verified
August 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Chen Zhinan-1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Hepatocellular Carcinoma
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedAdvanced Adult Hepatocellular Carcinoma | Advanced Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma | BCLC Stage B Adult Hepatocellular Carcinoma | BCLC Stage C Adult Hepatocellular CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | BCLC Stage A Hepatocellular CarcinomaUnited States
-
Jonsson Comprehensive Cancer CenterMerck Sharp & Dohme LLC; Highlight TherapeuticsTerminatedAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Refractory Hepatocellular CarcinomaUnited States
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCActive, not recruitingAdvanced Adult Hepatocellular Carcinoma | Child-Pugh Class A | Stage III Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular...United States
-
The University of Hong KongUnknownAdvanced Hepatocellular Carcinoma | Metastatic Hepatocellular CarcinomaChina
-
AmgenCompletedAdvanced Hepatocellular Carcinoma | Inoperable Hepatocellular Carcinoma
-
Mayo ClinicRecruitingAdvanced Hepatocellular Carcinoma | Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8United States
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityWithdrawnUnresectable Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Locally Advanced Hepatocellular Carcinoma
-
University of WashingtonExelixisTerminatedAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular CarcinomaUnited States
Clinical Trials on CD147-CART
-
Xijing HospitalUnknownRecurrent Glioblastoma | CD147 PositiveChina
-
Sinotau Pharmaceutical GroupNot yet recruiting
-
Peking University People's HospitalNot yet recruitingT-cell Non-Hodgkin's Lymphoma
-
University of PennsylvaniaNovartisActive, not recruitingMultiple MyelomaUnited States
-
University of Southern CaliforniaCompleted
-
Chinese University of Hong KongNot yet recruiting
-
Shanghai Unicar-Therapy Bio-medicine Technology...RecruitingAcute Myeloid LeukemiaChina
-
Shanghai Simnova Biotechnology Co.,Ltd.Active, not recruitingMultiple MyelomaChina
-
University of PennsylvaniaTerminatedLYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)United States
-
Laboratoires ArkopharmaCompleted